Brief: Reviva Pharmaceuticals Announces Global Enrollment Update For Phase 3 Study Evaluating Brilaroxazine For Schizophrenia

Reviva Pharmaceuticals Holdings

31/10/2022 12:06

Oct 31 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
 RVPH.O :
    * REVIVA PHARMACEUTICALS ANNOUNCES GLOBAL ENROLLMENT UPDATE
FOR
PIVOTAL PHASE 3 RECOVER STUDY EVALUATING BRILAROXAZINE FOR
SCHIZOPHRENIA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - ENROLLMENT ONGOING
AT
MULTIPLE SITES IN US AND EUROPE; SITE INITIATION IN ASIA
EXPECTED IN NOVEMBER 2022
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - ENROLLMENT ON
PACE, WITH
OVER 30% ENROLLED IN UNITED STATES
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. - TOPLINE DATA FOR
RECOVER
EVALUATING BRILAROXAZINE FOR SCHIZOPHRENIA EXPECTED IN MID-2023

Source text for Eikon:  ID:nGNXKlkjs 
Further company coverage:  RVPH.O 
 ((Reuters.Briefs@thomsonreuters.com;;))